Lung adenocarcinoma is a type of lung cancer that is a non-small cell carcinoma. Unlike squamous cell lung cancer, adenocarcinoma of the lung is more likely to occur in women and nonsmokers. It originates from the bronchial mucosa epithelium and, rarely, from the mucus glands of the large bronchi. The incidence is lower than that of squamous and undifferentiated carcinomas, and the age of onset is younger, with a relative prevalence in women. Most adenocarcinomas originate in the smaller bronchi and are peripheral lung cancers.
After radical lung cancer surgery, it is recommended to review every 3-6 months if recurrent or metastatic foci are found that are no longer indicative of surgery. The common regimen is pemetrexed + platinum; targeted therapy is feasible according to the presence or absence of genetic mutation targets; immunotherapy is also available for those with appropriate conditions; multiple treatment modalities are available to effectively increase the survival duration and improve the quality of survival.